Speakers
Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
6:10 pm | Chair’s Closing Remarks
Alison Crawford
Associate Director of Immuno-oncology
Regeneron
Pre-Conference Workshop
June 29, 2021
12:05 pm | Speaker Q&A
11:15 am | Examining Toxicity Mitigation Strategies To CD3 Bispecifics In Humanized Mouse Models
Marta Germani
Research Analyst
Beacon Targeted Therapies
Day One
Wednesday, June 30, 2021
8:20 am | Landscape Review of CD3 Bispecifics
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
Eric Vivier
Chief Scientific Officer
Innate Pharma
Day One
Wednesday, June 30, 2021
11:00 am | Multi-functional Natural Killer Cell Engagers
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
Mohamed Elmeliegy
Associate Director Clinical Pharmacology
Pfizer
Pre-Conference Workshop
June 29, 2021
12:45 pm | Round Table: Developing A Dosing Strategy For Clinical Trial Investigations
Matthew Weinstock
Chief Technology Officer
Absci
Day Two
Thursday, July 1, 2021
9:30 am | Production of T Cell Engagers and complex protein therapeutics using E. coli SoluProâ
9:45 am | Live Q&A - Ask our Speakers Your Burning Questions
Erin Meermeier
Senior Research Fellow
Mayo Clinic
Pre-Conference Workshop
June 29, 2021
1:45 pm | Developing Combination Approaches Using Immunocompetent Vk*MYChCRBN Genetically Engineered Humanized Model Of Multiple Myeloma
Maya Kotturi
Director of Preclinical Biomarkers
IGM Biosciences
Pre-Conference Workshop
June 29, 2021
2:10 pm | Developing A Preclinical Biomarker Strategy For Assessing Efficacy and Safety of Bispecific T Cell Engagers
Peter Pavlik
Director of Molecular Biology and Antibody Engineering
Aptevo Therapeutics
Day One
Wednesday, June 30, 2021
10:35 am | Live Q&A - Ask our Speakers Your Burning Questions
9:45 am | Engineering of APVO442, a bispecific molecule with high affinity tumor targeting and low affinity binding to CD3 to potentially improve efficacy in solid tumors
Catherine McMahan
Senior Director of Pharmacology & Cell Sciences
Aptevo Therapeutics
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Hilario Ramos
Senior Director of Immuno-Biology
Aptevo Therapeutics
Day One
Wednesday, June 30, 2021
4:00 pm | APVO603: A distinct dual agonistic bispecific approach to facilitate anti-tumor activity and overcome limitations of monoclonal OX-40 and 4-1BB targeting
4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions
Chris Hughes
CSO
Aracari Biosciences
Day One
Wednesday, June 30, 2021
12:45 pm | Live Q&A - Ask our Speakers Your Burning Questions
12:30 pm | The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery
James Keck
Senior Director, Innovation and Product Development
The Jackson Laboratory
Suhasini Iyer
Chief Development Officer
TeneoBio
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Pieter Fokko van Loo
Senior Director, Oncology - Immunology
Merus
Day One
Wednesday, June 30, 2021
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
11:25 am | Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers
Christian Klein
Department Head Cancer Immunotherapy Discovery
Roche
Day One
Wednesday, June 30, 2021
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
8:45 am | Novel Approaches for T-Cell Engagement
Bryan Irving
Chief Scientific Officer
Amunix Pharmaceuticals
Andrew Pierce
VP Translational Biology
Crescendo Biologics
Day One
Wednesday, June 30, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:30 pm | CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism
Nelly Kuklin
VP Immunology
Compass Therapeutics
Day One
Wednesday, June 30, 2021
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
11:50 am | Bispecific Anti-PD-1/PD-L1 Antibody CTX-8371 Promotes Immunological Synapse Formation & PD-1 Shedding With Superior Anti-Tumor Activity & Favorable Tolerability
Yiping Rong
Head of Discovery Biology
Harbour Biomed
Day One
Wednesday, June 30, 2021
4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions
3:35 pm | HBICETM-Based B7H4x4-1BB Bispecific Provides Tumor Specific 2nd Costimulatory Signal & Anti-Tumor Immune Response
Nicholas Huntington
Co-Founder & Chief Scientific Officer
oNKo-innate
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:05 pm | Tuning the NK Cell Response to Soluble Factors in the Tumor Microenvironment
Tatiana Novobrantseva
Co-Founder & Chief Scientific Officer
Verseau Therapeutics
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:30 pm | Macrophage Repolarization as a Key Strategy in Changing Tumor Microenvironment
Saileta Prabhu
VP/Global Head, Clinical Biomarker Innovation & Development
Takeda
Day Two
Thursday, July 1, 2021
4:35 pm | Live Q&A - Ask our Speakers Your Burning Questions
3:45 pm | ROI on Clinical Biomarkers, CDx and Precision Medicine
David DiLillo
Associate Director
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
10:35 am | Live Q&A - Ask our Speakers Your Burning Questions
10:10 am | Benchmarking T-cell -Redirecting Therapies for Cancer: Comparing Bispecifics & CAR T Cells
Patricia Giblin
VP of Biology
Revitope Oncology
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
10:50 am | Live Q&A - Ask our Speakers Your Burning Questions
10:00 am | Improving the Therapeutic Index with Guided Antibody Tumor Engagers (GATETM)
Maria Wendt
Head of Biologics Research & Global Head Digital Biologics Platform
Sanofi
Floris van Delft
Chief Scientific Officer
Synaffix
Day Two
Thursday, July 1, 2021
9:45 am | Live Q&A - Ask our Speakers Your Burning Questions
9:05 am | Generation of Bispecific & Trispecific T-Cell & NK Cell- Engagers From Any IgG Without Prior Reengineering
Fernanda Arnaldez
Executive Director - Medical & Global Clinical Development
MacroGenics
Wim van Schooten
Chief Scientific Officer
TeneoBio
Day Two
Thursday, July 1, 2021
1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions
1:30 pm | Safety & Efficacy of T-Cell Engagers with Low Agonist Activity in Oncology & Infectious Diseases
Chad May
SVP Research & Development
Maverick Therapeutics
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Brian Rabinovich
Director
EMD Serono
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Lukas Roth
Senior Scientist, Protein Engineering and Antibody Technologies
Merck KGaA
Day One
Wednesday, June 30, 2021
5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions
4:40 pm | Affinity Maturation of B7-H6 Translates Into Enhanced NK Cell-Mediated Tumor Cell Lysis & Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement
Michael Hedvat
Associate Director
Xencor
Day One
Wednesday, June 30, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
4:10 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:55 pm | Tumor-Targeted CD28 Costimulatory Bispecific Antibodies Enhance T-Cell Activation in Solid Tumors
Joachim Koch
Head of Translational Research & Innovation
Affimed GmbH
Day One
Wednesday, June 30, 2021
5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions
5:30 pm | Combination Therapies with Innate Cell Engagers to Fight for Patients in Need
Julie Bailis
Director of Research
Amgen
Day One
Wednesday, June 30, 2021
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
9:10 am | Targeting Prostate Cancer with T-Cell Engager Immune Therapies
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Janet Peper
Senior Scientist, Translational Science
Pieris Pharmaceuticals
Day One
Wednesday, June 30, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:05 pm | 4-BB Agonism in Immuno-Oncology - Presenting Our Immunotherapy Approaches Using Tumor-Localized 4-1BB Engagement
Divya Mathur
Director of Immuno-oncology
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Day Two
Thursday, July 1, 2021
8:30 am | Chair’s Opening Remarks
Nuzhat Pathan
Senior Director, Translational and Immuno-Oncology
Pfizer
Day Two
Thursday, July 1, 2021
4:35 pm | Live Q&A - Ask our Speakers Your Burning Questions
4:10 pm | Biomarker strategies for optimal Immuno-Oncology combinations
Danielle Dettling
Senior Director, Pre- Clinical Pharmacology
Maverick Therapeutics
Day Two
Thursday, July 1, 2021
10:25 am | Utilizing its conditionally activated COBRA platform in the solid tumor space to demonstrate an improved therapeutic window over conventional T-cell engagers
10:50 am | Live Q&A - Ask our Speakers Your Burning Questions
Gosia Nocula-Lugowska
Principal Scientist
Pfizer
Day Two
Thursday, July 1, 2021
8:40 am | Optimizing T-cell Bispecifics in the Treatment of Solid Tumors
9:45 am | Live Q&A - Ask our Speakers Your Burning Questions
Pre-Conference Workshop
June 29, 2021
12:05 pm | Speaker Q&A
11:40 am | Review Types and Sources of Toxicity for T-Cell Retargeting Bi and Multi-Specific Antibodies
Rick Austin
Vice President, Research
Harpoon Therapeutics
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:55 pm | Presentation Title To Be Announced
Hans van der Vliet
CSO
Lava Therapeutics
Day One
Wednesday, June 30, 2021
5:55 pm | Live Q&A - Ask our Speakers Your Burning Questions
5:05 pm | Bispecific Antibodies to Engage Vγ9Vδ2-T Cells for Cancer Immunotherapy
Bruce Keyt
Chief Scientific Officer
IGM Biosciences
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Day Two
Thursday, July 1, 2021